Stock GRANULES GRANULES INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Granules India Limited

Equities

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:46:56 2024-05-21 pm EDT 		5-day change 1st Jan Change
419 INR +2.41% Intraday chart for Granules India Limited +6.36% +3.93%
May. 15 Transcript : Granules India Limited, Q4 2024 Earnings Call, May 15, 2024
May. 15 Granules India Posts Decline in Fiscal Q4 Consolidated Net Profit, Revenue MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 29,060 36,510 75,120 75,964 70,374 99,153 - -
Enterprise Value (EV) 1 37,495 36,510 82,206 82,880 78,577 104,206 107,117 106,315
P/E ratio 12.3 x 10.9 x 13.8 x 18.5 x 13.8 x 25.7 x 17.2 x 13.7 x
Yield 0.87% 0.7% 0.49% 0.49% 0.52% 0.34% 0.34% 0.34%
Capitalization / Revenue 1.28 x 1.4 x 2.32 x 2.02 x 1.56 x 2.31 x 1.93 x 1.67 x
EV / Revenue 1.65 x 1.4 x 2.54 x 2.2 x 1.74 x 2.31 x 2.09 x 1.79 x
EV / EBITDA 9.76 x 6.95 x 9.61 x 11.5 x 8.6 x 12.2 x 9.58 x 8.07 x
EV / FCF -219 x 12.5 x 51 x -126 x 24 x 110 x 72.6 x 31.1 x
FCF Yield -0.46% 7.99% 1.96% -0.79% 4.18% 0.91% 1.38% 3.22%
Price to Book 1.9 x 1.98 x 3.46 x 2.94 x 2.48 x 3.14 x 2.61 x 2.21 x
Nbr of stocks (in thousands) 254,248 254,248 247,675 248,006 242,043 242,369 - -
Reference price 2 114.3 143.6 303.3 306.3 290.8 409.1 409.1 409.1
Announcement Date 5/9/19 6/2/20 5/11/21 5/18/22 5/16/23 5/15/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Marzo 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,792 25,986 32,375 37,649 45,119 45,064 51,275 59,343
EBITDA 1 3,840 5,253 8,552 7,222 9,138 8,560 11,184 13,179
EBIT 1 2,786 3,884 7,038 5,636 7,293 6,486 8,775 10,409
Operating Margin 12.22% 14.94% 21.74% 14.97% 16.16% 14.39% 17.11% 17.54%
Earnings before Tax (EBT) 1 2,768 4,256 7,044 5,580 6,872 5,472 7,795 9,718
Net income 1 2,364 3,354 5,495 4,128 5,166 4,053 5,844 7,338
Net margin 10.37% 12.91% 16.97% 10.96% 11.45% 8.99% 11.4% 12.37%
EPS 2 9.280 13.15 21.95 16.60 21.00 16.72 23.75 29.87
Free Cash Flow 1 -171.6 2,917 1,611 -656.5 3,281 979 1,475 3,424
FCF margin -0.75% 11.23% 4.98% -1.74% 7.27% 2.15% 2.88% 5.77%
FCF Conversion (EBITDA) - 55.53% 18.84% - 35.9% 11.3% 13.19% 25.98%
FCF Conversion (Net income) - 86.97% 29.33% - 63.51% 23.4% 25.24% 46.66%
Dividend per Share 2 1.000 1.000 1.500 1.500 1.500 1.375 1.375 1.375
Announcement Date 5/9/19 6/2/20 5/11/21 5/18/22 5/16/23 5/15/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 8,445 7,993 8,498 8,883 9,968 10,300 10,196 11,555 11,471 11,955 9,855 11,215 12,346 12,500
EBITDA 1 2,116 2,020 2,014 1,512 1,737 1,927 2,115 2,429 2,313 2,281 1,368 1,880 2,368 2,793
EBIT 1,747 1,575 1,620 1,113 1,345 1,525 - 1,988 1,829 1,794 - 1,354 1,869 2,068
Operating Margin 20.69% 19.71% 19.07% 12.53% 13.49% 14.81% - 17.21% 15.95% 15.01% - 12.07% 15.14% 16.54%
Earnings before Tax (EBT) 1 1,839 1,540 1,629 1,102 1,348 1,501 1,659 1,904 1,669 1,640 654.7 1,169 1,704 1,924
Net income 1 1,468 1,276 1,202 806.8 1,009 1,110 1,276 1,451 1,243 1,196 479 1,112 1,295 1,738
Net margin 17.38% 15.96% 14.14% 9.08% 10.12% 10.78% 12.51% 12.56% 10.84% 10% 4.86% 9.91% 10.49% 13.91%
EPS 2 - - - - - 4.460 5.130 5.820 5.100 4.930 1.980 - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 1/28/21 5/11/21 7/27/21 11/12/21 2/8/22 5/18/22 8/9/22 10/20/22 1/24/23 5/16/23 8/9/23 - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 8,434 - 7,086 6,916 8,203 8,126 7,964 7,162
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.196 x - 0.8285 x 0.9576 x 0.8976 x 0.9378 x 0.7121 x 0.5435 x
Free Cash Flow 1 -172 2,917 1,611 -657 3,281 979 1,475 3,424
ROE (net income / shareholders' equity) 16.7% 19.9% 27.4% 17.3% 19.1% 13.5% 16.4% 17.6%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 60.20 72.50 87.70 104.0 117.0 130.0 157.0 185.0
Cash Flow per Share - - - - - - - -
Capex 1 2,794 1,845 2,713 3,977 4,107 6,023 6,245 5,064
Capex / Sales 12.26% 7.1% 8.38% 10.56% 9.1% 13.2% 12.18% 8.53%
Announcement Date 5/9/19 6/2/20 5/11/21 5/18/22 5/16/23 5/15/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Granules India Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
409.1 INR
Average target price
473 INR
Spread / Average Target
+15.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GRANULES INDIA LIMITED Stock Granules India Limited
+3.93% 1.18B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.78% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.82% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 332B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.64% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-4.13% 210B
NOVARTIS AG Stock Novartis AG
+10.63% 209B
AMGEN INC. Stock Amgen Inc.
+9.32% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GRANULES Stock
  4. Financials Granules India Limited
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW